Alnylam: Positive KARDIA-2 Topline BP Study Results

 Study Met the Primary Endpoint Demonstrating Clinically Significant Systolic Blood Pressure Reductions at Month 3 When Zilebesiran Was Added to a Diuretic, Calcium-Channel Blocker or Angiotensin Receptor Blocker –

– Zilebesiran Demonstrated an Encouraging Safety and Tolerability Profile When Added to Standard of Care Antihypertensives –

– Study Results Support Potential for Biannual Dosing of Zilebesiran –

– Full Study Results to Be Presented as a Late-Breaking Clinical Trial at the 2024 American College of Cardiology Annual Scientific Session on April 7 –

– Alnylam and Roche Also Announce Initiation of the KARDIA-3 Phase 2 Study in Patients at High Cardiovascular Risk with Uncontrolled Hypertension Despite Standard of Care Antihypertensive Treatments –

https://www.biospace.com/article/releases/alnylam-reports-positive-kardia-2-topline-study-results-demonstrating-clinically-significant-blood-pressure-reductions-when-zilebesiran-is-added-to-standard-of-care-antihypertensives/